- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03741699
Recombinant LH Prior to Ovarian Stimulation in Poor Ovarian Responders (PRE-LH) (PRE-LH)
A Phase III Multicentre, Randomized, Unblinded Clinical Trial to Test the Effect of Treatment With Recombinant LH Prior to Controlled Ovarian Stimulation in Poor Ovarian Responder Women With an Advanced Maternal Age
Controlled ovarian stimulation (COS) is one of the first stages of assisted reproductive treatment. The goal is to mimic the ovarian cycle while stimulating the ovaries to overproduce eggs capable of being fertilized, thus maximizing the chances of reproductive success. The stimulation phase involves the use of different hormonal medications but requires tests to check the development of follicles, and hormonal adjustment to get the optimal ovarian response to stimulation.
However, between 9 to 24% of patients fail to respond adequately to standard stimulation protocols, resulting in Poor Ovarian Response (POR). In addition to the low oocyte production, POR results in a restricted number of good quality embryos with appropriate implantation potential, suggesting a compromised oocyte quality.
POR is one of the most challenging problems in reproductive medicine. Poor responders are difficult to treat since their response to stimulation tend to be deficient even when using different drugs or protocols. In recent years, different therapeutic alternatives have been proposed for these patients. However, to date, the optimal stimulation protocol has not yet been described and oocyte donation is often offered as their only option to achieve pregnancy.
Recently, evidence has emerged that supplementation with a specific hormone, luteinizing hormone (LH), during or prior to COS could lead to improved reproductive outcomes in poor responders by increasing the number of oocytes retrieved and improving their quality.
The present study aims to evaluate the effect of the treatment with LH prior to COS on the ovarian response in patients with POR and advanced maternal age, the worst prognosis but more frequent group of poor responders attending fertility clinics. We will assess whether LH treatment prior to COS increases the number and quality of oocytes retrieved in those patients and, finally, analyse the impact in their chances of getting pregnant and having a baby.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Manuel Muñoz, Dr.
- Phone Number: +34 966 01 24 90
- Email: Manuel.munoz@ivirma.com
Study Locations
-
-
-
Madrid, Spain, 28023
- Recruiting
- IVI Madrid
-
Contact:
- Juan Antonio García Velasco, Dr.
-
Principal Investigator:
- Juan Antonio García Velasco
-
Murcia, Spain, 30007
- Recruiting
- IVI Murcia
-
Contact:
- Jose Landeras Gutiérrez, Dr.
-
Principal Investigator:
- Jose Landeras Gutiérrez
-
-
Comunidad Valenciana
-
Alicante, Comunidad Valenciana, Spain, 03015
- Recruiting
- IVI Alicante
-
Contact:
- Manuel Muñoz Cantero, Dr.
-
Principal Investigator:
- Manuel Muñoz
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
-Patients with POR according to specific criteria that are in line with the criteria defined by the ESHRE (Bologna Criteria), according to which a patient is classified as a poor ovarian responder when she meets two of the three of the following criteria: I.- Previous episode of POR (≤3 oocytes) with conventional stimulation protocol II.- Abnormal ovarian reserve test with an antral follicle count (AFC) <5-7 and/or anti-mullerian hormone values (AMH) <0.5-1.1 ng/mL.
III.- Women ≥40 years old and/or who have any other risk factor for POR. In addition, two episodes of POR after maximal stimulation are sufficient to define a patient as poor responder in the absence of advanced maternal age or abnormal ovarian reserve test.
- - Women ≥35 to ≤43 years for COS and assisted reproduction techniques (ART).
- - Couple or single woman, accepting preimplantation genetic diagnosis (PGS) after blastocyst biopsy and delayed transfer for selection of euploid embryos.
- - Body Mass Index (BMI) between18 and 30 kg/m 2 , inclusive.
- - Ejaculatory sperm with concentration ≥ 5 mill spermatozoa/mL and ≥ 5 mill total spermatozoa progressive motility. Bank and cryopreserved semen allowed.
- - Informed consent completed, signed and dated.
Exclusion Criteria:
- - Cases of recurrent spontaneous miscarriage (≥2 clinical miscarriages) or implantation failure (after transfer of 6 good D3 embryos or 4 good blastocysts) will be excluded.
- - Use of testicular or epididymal spermatozoa as well as ejaculate with concentration < 5 mill spermatozoa/mL and < 5 mill total spermatozoa progressive motility.
- - Primary ovarian failure, PCOS (in accordance with the Rotterdam criteria) or ovary/s inaccessible for oocyte retrieval.
- - Anatomical uterine abnormalities and any endometrium or myometrium pathology (adenomyosis, polyps, myoma, etc.) that may interfere with implantation or pregnancy. Patients with previous polypectomy, myomectomy or surgery for septate/subseptate/arcuatus uterus should not be excluded.
- - Presence of unilateral or bilateral hydrosalpinx that has not been surgically removed or ligated.
- - Presence of level III-IV endometriosis.
- - History of tumours in the hypothalamus or pituitary gland, or ovarian, uterine or breast cancer.
- - Abnormal bleeding of undetermined origin.
- - Known infection with human immunodeficiency virus, active hepatitis B or C virus in the woman or her partner.
- - Known allergy or hypersensitivity to the drugs administered during the trial.
- - Concurrent significant medical pathologies that would endanger the patient's safety (uncontrolled thyroid or adrenal dysfunction, severe hepatic or renal impairment, etc.) or interfere with the test evaluations or the clinical outcomes (i.e. confirmed thrombophilia).
- - Use of concomitant medication or any other circumstances that, in the opinion of the investigator, interferes with the development of the trial or does not ensure the safety and efficacy of the data.
- - Simultaneous participation in another clinical trial or previous participation in this study.
- - Participation in another clinical study two months before inclusion in the present study that could affect its objectives.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm 1 - experimental group
Treatment with 150 IU/day rLH, administered subcutaneously for 4 consecutive days prior to COS (with a starting dose of 225 IU/day rFSH and 75 IU/day rLH for 18 days maximum in a short antagonist protocol).
|
Treatment with 150 IU/day rLH (Luveris 75 IU), administered subcutaneously for 4 consecutive days prior to COS (Controlled ovarian stimulation)
|
No Intervention: Arm 2 - control (no pre-treatment) group
The subjects assigned to this group will not receive any treatment in the four days prior to COS (with a starting dose of 225 IU/day rFSH and 75 IU/day rLH for 18 days maximum in a short antagonist protocol).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
number of oocytes retrieved
Time Frame: 37 days
|
number of oocytes retrieved
|
37 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of follicles >17 mm on the previous day or the day of GnRH agonist injection (Decapeptyl)
Time Frame: from day 8-12 to day 33-37
|
from day 8-12 to day 33-37
|
P 4 and E 2 levels on the previous day or the day of GnRH agonist injection
Time Frame: from day 8-12 to day 33-37
|
from day 8-12 to day 33-37
|
Duration of stimulation and total gonadotropin dose during COS
Time Frame: from day 8-12 to day 33-37
|
from day 8-12 to day 33-37
|
Serum hormonal profile before and after IMP treatment and after stimulation
Time Frame: from day 8-12 to day 33-37
|
from day 8-12 to day 33-37
|
Cycle cancellation rates (stimulation cycle cancelled prior to oocyte retrieval if there is no follicular response after 10 days of stimulation or due to premature ovulation at any time before oocyte retrieval)
Time Frame: from day 8-12 to day 33-37
|
from day 8-12 to day 33-37
|
Number of mature or metaphase II (MII) oocytes/number of oocytes retrieved per puncture
Time Frame: Day 37
|
Day 37
|
Number of retrieved oocytes/number of expected oocytes (follicles >15 mm on the day of GnRH agonist injection)
Time Frame: Day 37
|
Day 37
|
Fertilization rate
Time Frame: Day 38
|
Day 38
|
Hormonal profile in follicular fluid on the day of the puncture
Time Frame: Day 37
|
Day 37
|
Gene expression profile in granulosa cells
Time Frame: Day 37
|
Day 37
|
Apoptosis rate in granulosa cells
Time Frame: Day 37
|
Day 37
|
Morphological variables of embryonic quality
Time Frame: Day 38 to 43
|
Day 38 to 43
|
Blastocyst rate
Time Frame: Day 43
|
Day 43
|
Number of optimal embryos (type A or B, according to ASEBIR classification)
Time Frame: Day 43
|
Day 43
|
Number of euploid and aneuploid embryos
Time Frame: Day 50
|
Day 50
|
Stimulation cycle yield (number of frozen embryos).
Time Frame: Day 43
|
Day 43
|
Number of cycles with embryo transferred/ number of stimulation cycle started
Time Frame: Day 43
|
Day 43
|
Pregnancy rates (per stimulation cycle and embryo transfer)
Time Frame: Throughout the study, estimate 1 year
|
Throughout the study, estimate 1 year
|
Implantation rates
Time Frame: Throughout the study, estimate 1 year
|
Throughout the study, estimate 1 year
|
Ongoing pregnancy rates (per stimulation cycle and embryo transfer)
Time Frame: Throughout the study, estimate 1 year
|
Throughout the study, estimate 1 year
|
Clinical and biochemical miscarriages rates (per stimulation cycle and embryo transfer)
Time Frame: Throughout the study, estimate 1 year
|
Throughout the study, estimate 1 year
|
Ectopic pregnancy rates (per stimulation cycle and embryo transfer)
Time Frame: Throughout the study, estimate 1 year
|
Throughout the study, estimate 1 year
|
Live birth rates
Time Frame: Throughout the study, estimate 18 +/-3 months
|
Throughout the study, estimate 18 +/-3 months
|
Assessment and recording of adverse events
Time Frame: Throughout the study, estimate 18 +/-3 months
|
Throughout the study, estimate 18 +/-3 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Manuel Muñoz, Dr., Physician - Investigator
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1601-ALC-002-MM
- 2017-004298-15 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infertility, Female
-
Esraa Gamal AhmedAin Shams Maternity HospitalUnknownUnexplained Female Infertility
-
Pacific Fertility CenterTerminatedPrimary Female Infertility | Secondary Female Infertility
-
Assuta Hospital SystemsMaccabi Healthcare Services, IsraelCompletedInfertility, Female Infertility, Male InfertilityIsrael
-
Newlife Fertility CentreRecruitingInfertility | Infertility,Female | Infertility Unexplained | Infertility of Uterine Origin | Infertility; Female, NonimplantationCanada
-
Wake Forest University Health SciencesWithdrawnUterine Diseases | Endometriosis | Infertility Unexplained | Endometrial Diseases | Infertility; Female, NonimplantationUnited States
-
Cairo UniversityCompleted
-
Navy General Hospital, BeijingUnknownFemale Infertility Due to Nonimplantation of OvumChina
-
Sapientiae InstituteTerminated
-
Radboud University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentCompletedPregnancy | Male Infertility | Female InfertilityNetherlands
-
IVI MadridCompletedFemale Infertility Due to Advanced Maternal AgeSpain
Clinical Trials on Pre-treatment with rLH (Luveris 75 IU),
-
University Hospital, Basel, SwitzerlandRecruiting
-
EMD SeronoTerminatedHypogonadotropic HypogonadismUnited States
-
Hospital Authority, Hong KongUnknownCerumen Impaction of Both EarsHong Kong
-
Ferring PharmaceuticalsCompletedInfertility, FemaleChina
-
Beth Israel Deaconess Medical CenterOpenBiomeCompletedIrritable Bowel SyndromeUnited States
-
Ferring PharmaceuticalsCompleted
-
University Hospital, RouenCompleted
-
SFJ Pharmaceuticals, Inc.SFJ Pharmaceuticals, Inc.Terminated
-
Fundación Pública Andaluza para la gestión de la...Spanish Clinical Research Network - SCReN; CIBER (Infectious diseases)Recruiting
-
Bursa Uludag UniversitesiBursa Uludağ University Scientific Research Projects UnitRecruitingEarly Susceptibility-Weighted Imaging and Vessel-Wall Imaging Findings After Flow-Diversion Treatment of Intracranial AneurysmsTurkey